Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan's Purchase Of Matrix Will Speed Launch Of ANDAs

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition of the Indian drug maker would give Mylan an edge on generic R&D and production costs as well as access to European markets.

You may also be interested in...



Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion

Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.

Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion

Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.

Indian Drug Companies Increasingly Active In Global M&A

Indian drug companies are actively making acquisitions and partnering deals in Europe and the U.S. in order to expand their geographic reach

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel